Interní Med. 2011; 13(5): 196-198
Treatment of chronic viral hepatitides in 2011
- Klinika infekčních chorob, LF MU a FN Brno
In 2011, there will be a major change in the treatment of chronic infection with hepatitis C virus (HCV). The reason for this change is the
commercial availability of novel antiviral drugs for the treatment of chronic HCV infection – telaprevir and boceprevir – in combination
with pegylated interferon (PEG-IFN) alpha and ribavirin. These drugs are likely to be approved in the United States and the European
Union in june 2011. In patients not yet treated with antiviral drugs (treatment-naive ones) as well as in those in whom classical treatment
with PEG-IFN and ribavirin failed to eliminate HCV infection permanently, the triple combination therapy is significantly more effective
than the combination of PEG-IFN and ribavirin.
boceprevir, telaprevir.
Keywords: viral hepatitis, pegylated interferon α, standard interferon α, adefovir dipivoxil, entecavir, telbivudine, tenofovir, ribavirin,
Published: June 1, 2011 Show citation
References
- Urbánek P. Infekce virem hepatitidy C. Praha: Galén; 2004.
- Husa P. Virové hepatitidy. Praha: Galén; 2005.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
Go to original source... 
Go to PubMed... - Husa P, Plíšek S, Šperl J, Urbánek P, a kol. Diagnostika a léčba chronické hepatitidy B. Doporučený postup ČHS a SIL ČLS JEP. Datum vydání doporučení: duben 2009. 1) Prakt Lék 2009; 89: 167-176 2) Klin Mikrobiol Inf Lék 2009; 15: 65-76.
- Urbánek P, Husa P, Galský J, a kol. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Doporučený postup České hepatologické společnosti a Společnosti infekčního lékařství ČLS JEP. Datum vydání doporučení 18. března 2008. Čas Lék Čes 2008; 146: I-XII.
- Shiffman M, Berg T, Muir A, et al. Telaprevir in combination with peginterferon and ribavirin in genotype1 HCV treatment-naive patients, prior relapsers and prior non-responders: pooled analysis of PROVE1, PROVE2, PROVE3 and Study 107. Am J Gastroenterol 2010; 105 (Suppl 1): S102. Go to original source...
- Kwo PY, Lawitz EJ, McCone J. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2001; 376: 1224. Go to original source...